Sentences with phrase «effects of the drugs which»

However, the pain of the surgery mixed in with their pregnancy hormones and the side effects of the drugs which they unfortunately had to take, it very stressful all around.

The research adds to the debate over the health effects of the drug which helps women through menopause.

Not exact matches

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

Companies like U.S. biotech giant Gilead and the U.K.'s GlaxoSmithKline (the majority stakeholder in global HIV partnership ViiV Healthcare) have developed drugs that drastically lower the chance of HIV infection — or which simply lower the number of drugs you have to take to treat it, consequently curbing the risk of toxic side effects while simplifying medical regimens.

UniQure, for example, has developed a drug called Glybera, which is essentially a virus that reverses the effects of LPLD, a disease that prevents people from breaking down fats and can cause increased risk of pancreatitis.

The pink pill, which boosts dopamine and norepinephrine (both catalysts for sexual excitement) while reducing the inhibitory effects of serotonin in the brain's prefrontal cortex, is the first — and so far only — female libido drug to win FDA approval.

The treaty, which is still in effect, requires all countries part of the treaty to «prevent and combat» drugs and drug addicts and to enforce punishment against the unauthorized cultivation, production or possession of opium, coca (and its derivative cocaine), marijuana and other illegal substances.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The side effect was first observed earlier this month at the American Society of Hematology conference, where CEODavid Schenkein spoke with CNBC about the safety of one of the molecules in its drug, which was meant to treat pyruvate kinase deficiency, a rare, genetic anemia.

In an editorial accompanying the new study, Dr. Wilson Compton of the National Institute on Drug Abuse in Bethesda, Maryland, and colleagues say policymakers need to understand which parts of medical marijuana laws are tied with positive and negative effects.

KeyBioscience designed these drugs, which include BP - 089 and KBP - 056, to have the same broad mechanism of action as KBP - 042 but deliver different effects or potency because of changes to their engineering.

These healthcare brands will have the effect of soothing out the inevitable fluctuations that occur on the pharmaceutical side, though right now, Glaxo's portfolio is boasting robust growth from small - scale HIV drugs Triumeq and Trivicay (which, as the CEO noted in the last annual report, sport year - over-year sales growth of 41 % and 43 %, respectively).

Perhaps so many of these new drugs fail to have an effect because the basic research on which their development was based isn't valid.

Drug company scientists develop a drug with a range of physiological effects, none of which are terribly helpful, so the marketers must identify and promote a disease for the drug to treatDrug company scientists develop a drug with a range of physiological effects, none of which are terribly helpful, so the marketers must identify and promote a disease for the drug to treatdrug with a range of physiological effects, none of which are terribly helpful, so the marketers must identify and promote a disease for the drug to treatdrug to treat....

It tells the story of «the guinea pigs»» the people most likely to be research subjects in Phase I trials, which test the safety of a drug under development by giving it to healthy subjects and examining any side effects they experience.

To establish a link between capsaicin and endorphins, Etscorn used a drug called naxalone, which can reverse the effects of a heroin overdose by blocking brain receptors that respond to the heroin.

«No one explained that one of the side effects of this drug was dehydration, which significantly interferes with milk production,» she says.

However there are a few drugs which are known for causing extra or spontaneous milk flow (known as galactorrhea) as a side effect of their intended medical use.

Moms have fewer drugs or no drugs and experience less interventions and complications which means less risk of side effects for mom and baby

Drugs used in active management have documented risks for the mother, including death, and we do not know the long - term effects of these drugs, which are given at a critical stage of brain development, for the Drugs used in active management have documented risks for the mother, including death, and we do not know the long - term effects of these drugs, which are given at a critical stage of brain development, for the drugs, which are given at a critical stage of brain development, for the baby.

Garrison (personal communication) reports that Narcan, which is sometimes needed by the baby to counteract the sedating effect of pain - relieving drugs such as pethidine (demorol), given to the mother in labour, can be effectively administered via the mother's veins in third stage, waking up the newborn baby in a matter of seconds.

Synthetic oxytocin, which mimics the effects of natural oxytocin on a pregnant woman's uterus, was first marketed in the 1950's, and has largely replaced ergometrine, although a combination drug, called syntometrine, is still used, especially for severe haemorrhage.

Anti-anxiety drugs, antidepressants, and neuroleptic drugs have been placed in Table 4, «Drugs for Which the Effect on Nursing Infants is Unknown but May Be of Concern.&rdrugs, antidepressants, and neuroleptic drugs have been placed in Table 4, «Drugs for Which the Effect on Nursing Infants is Unknown but May Be of Concern.&rdrugs have been placed in Table 4, «Drugs for Which the Effect on Nursing Infants is Unknown but May Be of Concern.&rDrugs for Which the Effect on Nursing Infants is Unknown but May Be of Concern.»

Domperidone - A drug that has a side effect of increasing the hormone prolactin, which stimulates the cells in the mother's breast to produce milk.

Many moms use fewer drugs or no drugs, which means less risk of side effects for you and your baby, due to elimination of the

Eventually, along the legalisation process, Iran's high number of death sentences, which is a principle side - effect of the country's war on drugs, would be almost nullified.

Mayor Bill de Blasio and first lady Chirlane McCray announced naloxone — which essentially reverses the effect of an overdose — will be sold in about 190 pharmacies in the city as part of an initiative to combat prescription drug and heroin addiction in the five boroughs.

The bills, which will go into effect 60 days after being signed into law by Mayor Bill de Blasio, are meant to close loopholes that have made a 2012 statewide ban of K2 difficult to enforce, increase individual penalties for sale of the drug and strengthen the city's ability to shut down stores that are discovered to be selling it.

The psychoactive substances bill sought to crack down on legal highs — especially the new generation of drugs that are designed to mimic the effects of traditional illicit substances such as cannabis and ecstasy — which the Home Office says caused 129 deaths in 2015.

The committee recommends the issues of criminality and how much harm a drug causes be completely separated, with the Advisory Council on the Misuse of Drugs (ACMD), which advises ministers on classification, focusing primarily on its clinical and social effects.

The new definition reads: «A substance produces a psychoactive effect in a person if, by stimulating or depressing the person's central nervous system, it affects the person's mental functioning or emotional state; as measured by the production of a pharmacological response on the central nervous system or which produces a response in in - vitro tests qualitatively identical to substances controlled under the Misuse of Drugs Act 1971, and references to a substance's psychoactive effects are to be read accordingly.»

He says children with Dravet's syndrome need an oil extract of a specific strain that does not contain THC, which is the component in marijuana responsible for most of the drug's psychological effects.

Just last month GW announced the results of clinical trials which show that its super-strong, super-concentrated, 51 % THC skunk cannabis medicine Sativex has»... limited relevant adverse effects and - particularly reassuring - the drug does not appear to lead to withdrawal effects if patients suddenly stop using it.»

According to a sponsor of the bill, David Tubilio, a Yonkers Republican, the law will seek to blockade Westchester against the harmful effects of the drug, which elsewhere across the state and country is sold legally over-the-counter.

And some anticancer drugs mimic the effect — which points to the possibility of those drugs treating alcoholism.

Hannes Stockinger, the senior author of the study, adds: «If we coupled this delivery method with screening of patient's tumours for the presence of a unique surface protein, which we can target with the Fab fragment - functionalized liposomes, we might be able to treat tumours more efficiently and decrease the side effects of the delivered anti-cancer drugs substantially.

The alpha 2 and beta 2 adrenergic receptors, both of which are activated by epinephrine, but which can be differentiated by selective drugs, have opposite effects (inhibitory and stimulatory) on the adenylyl cyclase system.

One large clinical trial known as JUPITER reported in 2008 that rosuvastatin (Crestor) lowers the risk of heart attacks and other events by 44 percent in healthy subjects but experts have since raised questions about its methodology in part because the trial was stopped early, which might have created the effect of overestimating the drug's benefits.

Promisingly, another drug called imipramine, which belongs to the second main class of antidepressants, had similar effects on miRNA - 1202 to citalopram, when applied to neurons grown in the lab.

To probe the drug's effect on memory, Sorg's team placed pond snails in two pools of low - oxygen water, one of which was laced with meth.

Giving the bees a drug to block the neurochemical dopamine, which is related to the reward system in humans, largely reversed the effects of the treat, indicating that these effects were down to dopamine making them feel good.

The drug works to block release of substances at nerve endings, which, from effects in different nerves, will lead to reduced muscle contraction and less transmission of pain signals.

The animals» baseline pain threshold had changed, and the effect was something more than tolerance, in which the body requires increasing doses of a drug to get the same effect.

But nearly all of these drugs have severe cognitive side effects, which led researchers to speculate that some other mechanism must also be involved.

«In light of the present results, it would be worthwhile to investigate whether the administration of benzodiazepine - like drugs may be increasing the retention of highly arousing and negative memories, which would have a countertherapeutic effect,» they wrote.

Another benefit of three - drug combinations is that they could allow doctors to prescribe lower doses of each antibiotic, which could reduce side effects.

«This study is particularly interesting from a therapeutic perspective since montelukast is a safe drug with very few side - effects, which means it can be taken over a long period of time,» explains Professor Haeggström.

A second potential drug, Sephin1, which is still in animal testing, keeps oligodendrocytes alive without the side effects of Guanabenz, Popko says.

Professor Gabay summarises the results: «We were initially reassured by the safety profile: there were very few serious side effects, only one of which was possibly related to the drug itself.

The benefits of catching psychosis early were deemed to come at too high a price — over-reliance on antipsychotic drugs which have unpleasant side effects